Novartis Pharmaceuticals – Non-small Cell Lung Cancer (NSCLC)

Access Program Information

Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to
patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in
countries where ALK inhibitors are not approved or available. The protocol will further
evaluate the safety of LDK378 in patients with ALK(+) NSCLC.